AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 132 min read$TAK

Plump Andrew Stewart sold $2.8M of TAK

Plump Andrew Stewart (President, R&D) sold 165,393 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($2.83M total) on 2026-08-10.

Original reporting
SEC EDGAR · Plump Andrew Stewart
Published Aug 13, 2026, 1:50 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider selling activity, but it does not include any new company-specific business or financial developments.

02

Market read

Traders may monitor insider activity as a sentiment input, but the filing alone is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not state reasons for the sale, and the share price level ($17.10) may reflect normal trading rather than a new valuation signal.

Relevance 6/10Novelty 3/10Timing: filed Aug 12, transaction dated Aug 10 (insider sale disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd (TAK).

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda disclosed an insider open-market sale by its R&D President, Andrew Stewart, of 165,393 shares at $17.10 on Aug 10.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

Form 4 shows an open-market sale and explicitly notes no pre-arranged 10b5-1 plan, but it does not provide new operational, financial, or regulatory information.

Market effects

Sector

Minimal; insider sale does not change sector fundamentals or guidance.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan could be interpreted as less “mechanical,” but insider sales are still often driven by diversification or personal liquidity needs.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the subject of the Form 4 insider transaction.

  • insider
    Plump Andrew Stewart

    President, R&D at Takeda, reported an open-market sale of shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

AUG 24
$TAKMedAI 8/10

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.

thestarphoenix.com2 min
AUG 21
$TAKMedAI 8/10

Takeda Q1 adjusted EPS beats estimates despite slight sales dip

Takeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.

scanx.trade3 min
AUG 18
$TAKMedAI 8/10

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

smithsonianmag.com4 min
AUG 8
$TAKMedAI 8/10

Takeda (TAK) Q1 2026 Earnings Call Transcript

Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.

fool.com7 min